30 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
Inspections 100 Part III 101 Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11. Executive Compensation 101 Item 12. Security … ("Sarbanes-Oxley Act"), reduced disclosure obligations regarding executive compensation in POINT’s periodic reports and proxy statements, exemptions
424B5
PNT
POINT Biopharma Global Inc.
14 Sep 22
Prospectus supplement for primary offering
4:12pm
and (iii) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
In addition, the JOBS Act
424B5
PNT
POINT Biopharma Global Inc.
13 Sep 22
Prospectus supplement for primary offering
5:19pm
voting requirements and (iii) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
In addition
424B3
PNT
POINT Biopharma Global Inc.
11 Jul 22
Prospectus supplement
4:32pm
obligations regarding executive compensation in our periodic reports and proxy statements.
Further, Section 102(b)(1) of the JOBS Act exempts emerging … with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
POS AM
zj3mp
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
7jnxq7f2
1 Jul 22
Shelf registration
4:13pm
DEF 14A
ofo4buw9txd02o0c
28 Apr 22
Definitive proxy
8:36am
424B3
siltz
31 Mar 22
Prospectus supplement
11:42am
POS AM
mw0le7
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
bydnksxqs0wdx
5 Aug 21
Prospectus supplement
4:26pm
8-K
ndirx9o9y2dqhtwt
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
tjc7mbna7eu0txe2fy
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
glmaj
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
k7u00 u5e3
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm